anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aberrant activation of the epithelial-mesenchymal transition (EMT) pathway drives the development of solid tumors, which is precisely regulated by core EMT-related transcription factors, including Twist1. However, the expression pattern and regulatory mechanism of Twist1 in the progression of bladder cancer is still unclear. In this study, we explore the role of Twist1 in the progression of bladder cancer. We discovered that the EMT regulon Twist1 protein, but not Twist1 mRNA, is overexpressed in bladder cancer samples using RT-qPCR, western blot and immunohistochemistry (IHC). Mechanistically, co-immunoprecipitation (Co-IP) coupled with liquid chromatography and tandem mass spectrometry identified USP5 as a binding partner of Twist1, and the binding of Twist1 to ubiquitin-specific protease 5 (USP5) stabilizes Twist through its deubiquitinase activity to activate the EMT. Further studies found that USP5 depletion reduces cell proliferation, invasion and the EMT in bladder cancer cells, and ectopic expression of Twist1 rescues the adverse effects of USP5 loss on cell invasion and the EMT. A xenograft tumor model was used to reconfirmed the inhibitor effect of silencing USP5 expression on tumorigenesis in vivo. In addition, USP5 protein levels are significantly elevated and positively associated with Twist1 levels in clinical bladder cancer samples. Collectively, our study revealed that USP5-Twist1 axis is a novel regulatory mechanism driving bladder cancer progression and that approaches targeting USP5 may become a promising cancer treatment strategy.
At initiation of surgical preparation, participants randomized to the placebo treatment arm will receive 0.9% sodium chloride (salt water). It will be matched in appearance, volume, and administration to the active treatment arm with tranexamic acid. If no unacceptable toxicities occur, a second dose of placebo IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
Group CBT for PPD. Women in the treatment group will attend a 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by lay-peers.
PURPOSE: Recurrent head and neck cancer poses difficult management. Even after salvage surgery, many patients are considered high-risk for further recurrence and benefit from reirradiation, despite the sequelae such as chronic wounds, tissue necrosis, osteoradionecrosis and vascular damage associated with re-irradiation. Free flaps not only enable the reconstruction following salvage surgery, but there has been limited studies suggesting that free flap reconstruction may reduce the amount of reirradiation complications. However, there are no studies to date specifically examining the effects of osteocutaneous free flap reconstruction upon reirradiation outcomes.
MATERIALS AND METHODS: In this retrospective study, patients with recurrent head and neck cancer that had a history of prior head and neck radiation who underwent salvage surgery with osteocutaneous free flaps followed by reirradiation were identified. Descriptive statistics were performed to assess outcomes.
RESULTS: Five patients met criteria. Complications included chronic wound infection in one patient, fistula in one patient, plate exposure in two patients and plate removal in one patient. No patients had osteoradionecrosis or carotid rupture after reirradiation. There was an association between complications and further local disease recurrence. All patients were tube feed dependent at their most recent follow-up and two patients were tracheostomy dependent 12 months post-irradiation. Two patients had disease recurrence. Median overall survival was 16 months after reirradiation.
CONCLUSIONS: Osteocutaneous free flap surgery with reirradiation may result in high rates of complications and low functional status with an equivocal improvement in survival. Larger studies are needed to substantiate these findings and assess the risk-benefit analysis.
An extractable device (10) is used to insert a medicinal filling into an animal tissue. The device comprises a filling member (20) and a pasty medicine. The filling member (20) is made of a flexible and hermetic wall (21) and is provided with a holding portion (22) and an injection port (23) via which the pasty medicine is injected into the holding portion (22) after the filling member (20) is inserted into the animal tissue. The holding portion (22) is provided with an opening (24) which is releasably lashed by one end of one or more threads (50,51) so as to make the opening leakproof. Upon completion of solidification of the pasty medicine in the holding portion (22) of the filling member (20), other end of the thread (50,51) is pulled to unlash the opening (24) of the holding portion (22), thereby enabling the filling member (20) to be extracted from the animal tissue so as to leave only the medicine in the animal tissue. <IMAGE>
FIELD: medicine; pharmaceutics.SUBSTANCE: group of inventions relates to a powder composition for preventing and/or treating inflammation or pain, a method for production thereof. A method for producing the powder composition, comprising the following steps: a) dispersing a lipophilic extract ofEchinacea spp. or plant lipophilic extract containing alkylamides, selected fromZanthoxylum spp. orAcmella spp., and a lipophilic extract ofZingiber officinalein at least one polar organic solvent selected from ethyl acetate and ethyl alcohol, and holding while stirring until complete or partial joint solubilization of the lipophilic extracts in an organic solvent to obtain a solution or suspension; optional heating; b) adding at least one sunflower lecithin to the solution or suspension of lipophilic extracts and holding the mixture while stirring until complete or partial co-solubilization of the lecithin; optional heating; c) removing the organic solvent to obtain a powder composition. Powder composition for preventing and/or treating inflammation or pain, obtained using the above production method. A pharmaceutical preparation for preventing and/or treating inflammation or pain, containing a powder composition and at least one physiologically acceptable excipient and/or carrier. A nutraceutical preparation for preventing and/or treating inflammation or pain, containing a powder composition and at least one physiologically acceptable excipient and/or carrier. A cosmetic preparation for preventing and/or treating inflammation or pain, containing a powder composition and at least one physiologically acceptable excipient and/or carrier. Use of the composition containing the powder composition for preventing and/or treating inflammation or pain.EFFECT: above-described composition demonstrates high solubility of active ingredients in gastric juice, is characterized by fast and effective absorption of active ingredients and, as a result, fast onset of their pharmacological activity, effective for preventing and/or treating inflammation or pain.13 cl, 10 ex
Occupational noise exposure continues to be a prevalent hazard in many industries. While the proliferation of noise dosimeters and wearable devices has made it easier to assess a worker's exposure to noise, many employees exposed to hazardous (i.e., >85 dBA) levels of noise may go their entire career without ever having their personal noise levels measured. In contrast to other occupational exposures, noise is easily perceived by the individual exposed, allowing them to develop subjective judgments regarding its characteristics. To determine whether such self-reported exposures to occupational noise are associated with hearing loss, this analysis used audiometric data and self-reported occupational exposure to loud noise from the National Health and Nutrition Examination Survey (NHANES), which has collected such data from 1999 to May 2020. Linear and logistic regressions models found a statistically significant association between self-reported noise exposure and worsened hearing at the 3, 4, 6, and 8 kHz hearing frequency as well as an elevated odds ratio for the development of hearing loss greater than 25 dB at the 2, 3, and 4 kHz audiometric frequencies. The results of this analysis suggest that in the absence of exposure measurements, workers are likely able to detect exposure to hazardous levels of noise. In these instances, additional measurements should be collected to determine if the workers should be enrolled in a hearing conservation program.
The present invention teaches a method, system and process for curing, treating and diagnosing arthritis, diabetes and other related autoimmune diseases. By intercepting and mitigating the disease process at the point of origination prevents the disease from developing and stops the lineage of cells causing disease symptoms. This fundamental system addresses cellular events where the immune reaction is emerging thereby preventing advance of the cascade that feeds the disease. Modulating activity of the errant protein at this initiating point in the immune response blocks the autoimmune cascade and prevents formation of secondary and tertiary effects that will characterize the disease. As the cascade progresses, the number of participating enzymes and pathways compounds so that each progression step further from the initiation point requires increasingly complex therapies. Thus, by treating the primary cause, secondary and tertiary symptoms do not appear. This avoids the side effects observed in multi-faceted approaches presently used to manage the disease symptoms rather than disease causation.
PURPOSE:To mold a powdered crude drug in a form of ready internal use without losing active ingredients, by pressurizing powdered Japanese or Chinese crude drug into a sheet form without adding water or an organic solvent, crushing and sizing the molded powder to a given size. CONSTITUTION:A Japanese or Chinese crude drug is cut to a size of about 1cm, put in a hermetically sealed container, frozen with injected liquid nitrogen and powdered in a pulverizer to provide a powdered Japanese or Chinese crude drug having 20-50mu size. The powder is then pressurized under 80-100kg/cm<2> pressure using a pressure roller and molded into a sheet form having 1.0-1.5mm thickness. In the process, pressurizing is carried out without using water or an organic solvent. The obtained sheet material is further crushed and sieved into granules having 30-150 mesh size or fine particles of 180-500mu size to afford the aimed substance. Essential oil ingredients or trace amounts of water in cells ooze out simply by pressurizing to provide a binder and molding can be carried out. Since water or organic solvent is not used, drying steps are omitted and crude drugs equal to those of original crude drugs are obtained without deterioration or denaturation.
Patients with relapsed /refractory aggressive B cell lymphoma usually have a poor prognosis. These patients cannot be treated successfully or tolered with the conventional chemotherapy. Epigenetic changes in B-cell lymphoma. Thus, epigenetic agents may offer potential improvment of clinical outcomes. Chidamide is a new type of oral histone deacetylase inhibitor. Our exploratory research found that Chidamide was effect in some relapsed /refractory B cell lymphoma patients

. Thus, we will evaluate the efficacy and safety of Chidamide in the patients with aggressive relapsed refractory B cell lymphoma failed from second line chemotherapy.
Adverse reactions at therapeutic doses are usually minimal and transient. On long-term use of dipyridamole tablets initial side effects usually disappear. The following reactions in Table 1 were reported in two heart valve replacement trials comparing dipyridamole tablets and war- farin therapy to either warfarin alone or warfarin and placebo:

Other reactions from uncontrolled studies include diarrhea, vomiting, flushing and pruritus. In addition, angina pectoris has been reported rarely and there have been rare reports of liver dysfunction. On those uncommon occasions when adverse reactions have been persistent or intolerable, they have ceased on withdrawal of the medication.

When dipyridamole tablets USP were administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone. In rare cases, increased bleeding during or after surgery has been observed.

In post-marketing reporting experience, there have been rare reports of hypersensitivity reac- tions (such as rash, urticaria, severe bronchospasm, and angioedema), larynx edema, fatigue, malaise, myalgia, arthritis, nausea, dyspepsia, paresthesia, hepatitis, thrombocytopenia, alo- pecia, cholelithiasis, hypotension, palpitation, and tachycardia.
Participants in the waitlist control group will not receive any intervention. They will continue usual care and will be asked to complete the self-reported questionnaires at baseline, 6, and 12-week. Participants n this group receive their personalized protocol at the end of 12 weeks after completing all the data collection.
Participants will attend 3 visits (V0, V1, V2). Visit 0 is a screening/baseline visit (5 to 10 days before Visit 1), where participants will be checked for inclusion and exclusion criteria, and undergo a lactose challenge (drink a cup of lactose containing water) followed by a hydrogen breath test (HBT) and Carbohydrate Perception Questionnaire (CPQ) measured at intervals over 3 hours. At Visit 1, eligible participants are randomized into one of the four study arms: Lactase and bacterial strain combination in a capsule; lactase and bacterial strain combination in separate capsules, lactase only, or placebo. Each Visit 1 and Visit 2 takes about 8 hours, where participants take the investigational product (IP) before the first lactose challenge (with first HBT and first CPQ for 3 hours), followed by a 2-hour break with standardized meal provided, and undergo a second lactose challenge (with second HBT and second CPQ for another 3 hours). Visit 2 is scheduled one week after Visit 1, where participants take the IP once daily at home for a week and fill in a diary between Visit 1 and 2. Stool samples are collected at Visit 1 and 2.
Novel polypeptides or derivatives comprising cdk2 binding site are disclosed. The novel polypeptides or derivatives have growth suppressive activity. Nucleic acids encoding those polypeptides are also disclosed. The polypeptides identified herein are also useful in methods for treating or preventing cancer. The treatment methods comprise administration of the polypeptide to the patient. The methods also comprise contacting the sample with the above-described polypeptide or derivative, wherein the polypeptide or derivative also comprises a covalently attached detectable moiety, then determining whether the polypeptide or derivative is binding cdk2 from the sample.
Cystic fibrosis is a recessive autosomic fatal disease, affecting about 6000 people in France. Thanks to progress in symptomatic care, median survival is increasing. The lung involvement is the most common and responsible for most deaths. The evaluation of respiratory disease severity is based on pulmonary functional tests (PFT) and imaging. Multi-slice computed tomography (CT) is the method of reference to quantify lung involvement in cystic fibrosis. It detects respiratory lung involvement earlier than PFT, and it reveals lesions associated with the onset of respiratory exacerbations, the mortality increase and the reduction of quality of life. However CT provides ionizing radiation, thus limiting the possibility of long-term follow-up. MRI is a non-ionizing 3D imaging technique; nevertheless, lung MRI is technically challenging with the result that it is currently not used in routine practice. Indeed, both low proton density and susceptibility effects lead to very low signal intensity derived from lung parenchyma. Recently, pulse sequences with ultrashort echo time (UTE) have been implemented by the use of half radio-frequency excitations and radial projection reconstruction. These UTE sequences make it theoretically possible to retrieve more signal from the lung parenchyma. The investigators aim at using 3D T1-weighted UTE pulse sequences on a 1.5T magnet (Avanto dot, Siemens) in cystic fibrosis patients in order to assess lung involvement severity. Thirty three cystic fibrosis adults are expected to take part in the study. All will benefit from PFT, CT and MRI. The investigators' strategy is to establish a semi quantitative score of pulmonary severity (Helbich score) using MRI and CT in subjects, testing for correlations between MRI and CT measurements and assessing the reproducibility of lung lesions quantification using MRI. The investigators' objective is to demonstrate that MRI-UTE pulse sequence at 1.5T is accurate and reproducible in evaluating and quantifying pulmonary involvement in cystic fibrosis.
The study design will detect levels of patient dysesthesia in response to Capsadyn using a three-arm, group comparison. Capsadyn will be compared to an active control \[capsaicin alone (Cap)\], and to a placebo cream alone (PL). The design will use a double-blind for assignment of test article to the three arms. Both the test article administrator and patient will be blinded to test article identity. The test article will be packaged in a coded, white-label, jar with cotton swab applicator.

Participants. Participants for the clinical trial will be recruited through the Carilion Clinic Dermatology Department in Roanoke, VA. In order to minimize the skin area exposed to capsaicin, test articles will be administered to about an 8 cm2 area of the volar forearm. Subject will be informed of the possibility of a transient capsaicin-induced burning sensation along with redness.

Study Groups. The groups are designated Pal and Cap or PL, a placebo (PL) group. The capsaicin drugs are topical analgesics for the temporary relief of minor aches and pains of muscles and joints associated with arthritis. Pal is 0.25% palmitated capsaicin. Cap is 0.10% capsaicin alone and is an active comparator. PL is vehicle alone. Test articles will be balanced arm-to-arm by Pal/Cap, Pal/PL, Cap/PL. Pretest baseline scores will be compared to treatment scores by one-way ANOVA followed by post-hoc analyses for Pal vs PL, Pal vs Cap, and Cap vs PL.

An active comparator is used since non-palmitated capsaicin (unprotected) produces heat. The sensory stimuli would break a neutral control such as vehicle alone. Zostrix at 0.1% capsaicin was used as the active comparator (Cap), a commercially-available topical capsaicin analgesic sold over-the-counter. The concentration of 0.25% capsaicin for Capsadyn (Pal), was based on the upper-limit concentration for capsaicin as specified by the FDA Tentative Final Monograph. A PL group is included since the placebo effect has to be assumed to be intrinsic to pharmaceutical intervention studies. If a placebo effect occurs that would interfere with assessment of the test article intervention, then those assessments can be evaluated with respect to the placebo group.
OVERVIEW: The roadmap adopted by the World Health Organization (WHO) for eliminating neglected tropical diseases aims to eliminate schistosomiasis, as a public health concern, by 2030. While progress has been made towards reducing schistosomiasis morbidity control in several sub-Saharan African countries, there is still more that needs to be done. Proper surveillance using accurate diagnostics with acceptable sensitivity and specificity is essential for evaluating the success of all efforts against schistosomiasis. Microscopy, despite its low sensitivity, remains the gold standard approach for diagnosing the disease. Although many efforts have been made to develop new diagnostics based on circulating parasite proteins, genetic markers, schistosome egg morphology, and their paramagnetic properties, none has been robust enough to replace microscopy. This review highlights common diagnostic approaches for detecting schistosomiasis in field and clinical settings, major challenges, and provides new and novel opportunities and diagnosis pathways that will be critical in supporting elimination of schistosomiasis.
METHODS: We searched for relevant and reliable published literature from PubMed, Scopus, google scholar, and Web of science. The search strategies were primarily determined by subtopic, and hence the following words were used (schistosom*, diagnosis, Kato-Katz, antibody test, circulating antigen, POC-CCA, UCP-LF-CAA, molecular diagnostics, nucleic acid amplification test, microfluidics, lab-on a disk, lab-on chip, recombinase polymerase amplification (RPA), LAMP, portable sequencer, nanobody test, identical multi-repeat sequences, diagnostic TPPs, REASSURED, extraction free), and Boolean operators AND and/OR were used to refine the searching capacity. Due to the global public health nature of schistosomiasis, we also searched for reliable documents, reports, and research papers published by international health organizations, World Health Organization (WHO), and Center for Disease control and Elimination.
The present invention relates to an inhibitor of FXYD2, wherein the inhibitor reduces expression and/or activity of FXYD2 and targets at least the region comprising or consisting of nucleotides 219 to 229 of SEQ ID NO:3 in a subject in need thereof. The inventors have demonstrated that targeting the FXYD2 region can be used to inhibit and/or reduce expression and/or activity of FXYD 2. They designed and synthesized an antisense oligonucleotide (SEQ ID NO:4) targeting the rat and human FXYD2 genes. They performed intrathecal injection of FXYD2 optimized ASO in two rat pain models (neuropathic pain and inflammatory pain). They have demonstrated that FXYD2ASO is effective in reducing its expression in rat Dorsal Root Ganglia (DRG). They have demonstrated that FXYD2ASO significantly reduces neuropathic pain in a Spinal Nerve Ligation (SNL) rat model, and that the analgesic effect of FXYD2ASO on neuropathic pain is greater than the leading Ziconotide in the market today. They also showed that FXYD2ASO significantly reduced inflammatory pain in a Complete Freund's Adjuvant (CFA) induced rat model.
The invention provides four beta-cyclodextrin-modified tetrahydro-beta-carboline carboxylic acid derivatives represented by 10a-d, and a preparation method thereof. The invention further provides the functions of the compounds in resisting platelet aggregation and further in resisting thrombosis, through the evaluations of the anti-thrombotic effects of the compounds on rats carotid arterial and venous bypass circulation thrombosis models and in-vitro anti-platelet-aggregation effects of the compounds. The method provided by the invention is simple. The raw materials are easy to obtain, and are safe and cheap. Obtained products have anti-platelet-aggregation and anti-thrombotic activities, such that the products are beneficial for the developments of anti-platelet medicines. Therefore, the four beta-cyclodextrin-modified tetrahydro-beta-carboline carboxylic acid derivatives provided by the invention have clinical application potentials as anti-thrombotic agents.